Form 4: Vaxart's Chief Medical Officer, James F. Cummings, Reports Changes in Beneficial Ownership

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports a transaction involving the withholding of shares to cover income tax obligations related to vested RSUs.

Summary

• On March 28, 2025, James F. Cummings, the Chief Medical Officer of Vaxart, Inc., had 3,292 shares of common stock withheld by the issuer to satisfy income tax obligations.
• This was in connection with the net settlement of Restricted Stock Units (RSUs) that vested on the same date.
• The price per share for the transaction was $0.4212.
• Following this transaction, Cummings beneficially owns 745,757 shares of Vaxart common stock directly.

Sentiment

Score: 5

Explanation: This is a neutral filing related to standard tax procedures for vested equity. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard process of tax obligation fulfillment related to vested equity compensation.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it involves the withholding of shares for tax purposes, not a sale on the open market.

Key Dates

Keywords

Vaxart, James F. Cummings, Chief Medical Officer, Form 4, Beneficial Ownership, VXRT, RSUs, Stock Withholding, Tax Obligations